Antivirals in Development Pipeline

2006 Antiretrovirals in Development Pipeline

Prepared for
Treatment Action Group
By Rob Camp •

Phase of Development	NRTI	NNRTI	PI	EI *	Integrase Inhibitors	Other
Phase I	KP-1461, mutagenic deoxyribo-nucleoside, Koronis		PPL-100, Merck	BMS-378806, gp120 blocker, BMS	GSK364735, GSK/Shionogi	BI-201, Tat inhibiting mAb, BioInvent
	Alovudine (fosalvudine tidoxil, FLT), Heidelberg Pharma			TAK-652, Takeda
				004, mAB, Human Genome Sciences
				Suc-HSA, fusion inhibitor, Sanquin
Phase Ib/II	Racivir (PSI 5004), Pharmasset	BILR 355/r BS, Boehringer Ingelheim		AMD-070, CXCR4 antagonist, Anormed		Valproic acid, [Depakote™, Abbott], ACTG
	Apricitabine (AVX 754), Avexa			PRO-140, MAb, Progenics		Bevirimat (PA-457), Budding inhibitor, Panacos
	Elvucitabine (ACH-126), Achillion			INCB9471, CCR5 inhibitor, Incyte
				HGS004, CCR5 mAb, Human Genome Sciences
Phase II		Rilpivirine, TMC-278, Tibotec/J&J	Brecanavir/r (640385), GSK	Vicriviroc, CCR5 antagonist, Schering Plough	GS-9137, Gilead
				TNX-355, Anti-CD4 MAb, Tanox/Biogen
Phase III		Etravirine (TMC125), Tibotec/J&J		Maraviroc, CCR5 antagonist, Pfizer	MK-0518, Merck
Notes: * entry inhibitors, including CCR5 and CXCR4 receptor binding antagonists and CD4 monoclonal antibodies directed at binding, fusion, and entry. link to abstract/background material from CROI 2005. On hold or stopped. link to abstract/background material from XIIIth Conference on Retroviruses and Opportunistic Infections, Denver, US, 5-8 February, 2006.